代谢组学技术在疾病诊断中的应用

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (1): 11-15.

代谢组学技术在疾病诊断中的应用

管恩泽¹, 朱萱萱², 王广基³, 郝海平³, 丁杨¹

¹南京中医药大学药学院, 南京 210029, 江苏;
²江苏省中医院临床研究所药理室, 南京 210029, 江苏;
³中国药科大学药学院药代动力学实验室, 南京 210038, 江苏

收稿日期:2007-09-07 修回日期:2007-12-10 出版日期:2008-01-26 发布日期:2020-10-13
通讯作者: 朱萱萱,女, 教授,主任药师, 硕士生导师,研究方向:药理学。Tel:025-86555797 　E-mail: zhuxuanxuan@sina.com
作者简介:管恩泽, 男, 硕士研究生, 研究方向:药理学。Tel:15895870478 E-mail: gez7995@163.com
基金资助:
南京市科技局资助课题(200605012)

Metabonomics technology and its applications in disease diagnosis

GUAN En-ze¹, ZHU Xuan-xuan², WANG Guang-ji³, HAO Hai-ping³, DING Yang¹

¹Department of Pharmacology, Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu,China;
²Pharmacology Laboratory of Clinical Institute, Jiangsu Provincial Hospital of Trditional Chinese Medicine,Nanjing 210029, Jiangsu, China;
³Laboratory of Pharmacokinetics, China Pharmaceutical University, Nanjing 210038, Jiangsu, China

Received:2007-09-07 Revised:2007-12-10 Online:2008-01-26 Published:2020-10-13

摘要/Abstract

摘要： 代谢组学是一门在新陈代谢的动态进程中, 系统研究代谢产物的变化规律, 揭示机体生命活动代谢本质的科学。本文对代谢组学的概念、特点、研究方向及研究方法作了简要介绍, 综述了当前代谢组学技术在临床疾病诊断中的应用, 并对代谢组学的发展作了展望。

关键词: 代谢组学, 疾病诊断, 生物标志物

Abstract: Metabonomics is the scientific technology to study the regularity of metabolic products in metabolic proceeding and to reveal the essence of vital movement. Metabonomics technologies are introduced in the following aspects: the concepts, characteristics, research direction and approaches. Metabonomics technology and its applications in disease diagnosis are reviewed in this paper.

Key words: metabonomics, diagnosis, biomarker

中图分类号:

R969.1

管恩泽, 朱萱萱, 王广基, 郝海平, 丁杨. 代谢组学技术在疾病诊断中的应用[J]. 中国临床药理学与治疗学, 2008, 13(1): 11-15.

GUAN En-ze, ZHU Xuan-xuan, WANG Guang-ji, HAO Hai-ping, DING Yang. Metabonomics technology and its applications in disease diagnosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 11-15.

参考文献

[1] Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research[J]. Nature, 2003, 422(6934):835-847.
[2] John R. Metabolomics-an important emerging science. Business briefing: pharmatech[J]. Drug Discov Today, 2004, 1: 51-54.
[3] Lindon JC, Holmes E, Nicholson JK. So what's the deal with metabonomics[J] ? Anal Chem, 2003, 75(17):384A-391A.
[4] Nicholson JK, Wilson ID. Understanding global systems biology: metabonomics and the continuum of metabolism[J]. Nat Rev Drug Discover, 2003, 2(8):668-676.
[5] Ideker T, Thorsson V, Ranish JA, et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network[J]. Science, 2001, 292(5518):929-934.
[6] Oliver SG, Winson MK, Kell DB, et al. Systematic functional analysis of the yeast genome[J]. Trends Biotechnel, 1998, 16(9):373.
[7] Oliver SG. Yeast as an avigational tool in genome analysis[J]. Microbiology, 1997, 143(2):1483-1487.
[8] Nicholson JK, Lindon JC, Holmes E. Metabonomics:understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11):1181-1189.
[9] Fiehn O, Kopka J, Dormann P, et al. Metabolite profiling for plant functional genomics[J]. Nat Biotechnol, 2000, 18(11):1157-1161.
[10] Schmidt CW. Metabolomics:what's happening downstream of DNA[J]. Environ Health Perspect, 2004, 112(7):A410.
[11] Griffin JL, Walker LA, Garrod S, et al. NMR spectroscopy based metabonomic studies on the comparative biochemistry of the kidney and urine of the bank vole (Clethrionomys glareolus), wood mouse (Apodemus sylvaticus), white toothed shrew (Crocidura suaveolens)and the laboratory rat[J]. Comp Biochem Phy siol B Biochem Mol Biol, 2000, 127(3):357-367.
[12] Huhn SD, Szabo CM, Gass JH, et al. Metabolic profiling of normal and hypertensive rat kidney tissues by hrMAS-NMR spectroscopy[J]. Anal Bioanal Chem, 2004, 378(6):1511-1519.
[13] Taylor J, King RD, Altmann T, et al. Application of metabolomics to plant genotype discrimination using statistics and machine learning[J]. Bioinformatics, 2002, 18(3):241-248.
[14] Plumb RS, Stumpf CL, Granger JH, et al. Use of liquid chromatography time-of-flight masss pectrom etry and multivariate statisticalan alysis shows promise for the detection of drug metabolites in biological fluids[J]. Rapid Commun Mass Spectrom, 2003, 17(23):2632-2638.
[15] Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring drug safety assessment and disease diagnosis[J]. Biomarkers, 2004, 9(1):1-31.
[16] Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics[J]. Nat Med, 2002, 8(12):1439-1444.
[17] Sabatine MS, Liu E,Morrow DA, et al. Metabolomic identification of novel biomarkers of myocardial ischemia[J]. Circulation, 2005;112(25):3868-3875.
[18] Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease[J]. Proteome Res, 2007, 6(2):546-551.
[19] Yin P, Zhao X, Li Q, et al. Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC Q-TOF MS)[J]. Proteome Res, 2006, 5(9):2135-2143.
[20] Yang J, Xu GW, Zheng YF, et al. Strategy for metabonomics research based on high-performance liquid chromatography and liquid chromatography coupled with tandem mass spectrometry[J]. J Chromatogr A, 2005, 1084:214-221.
[21] Robertson DG, Reily MD, Sigler RE, et al. Metabonomics: evaluation of nuclear magnetic resonance (NMR)and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants[J]. Toxicol Sci, 2000, 57(2):326-337.
[22] Psihogios NG, Kalaitzidis RG, Dimou S, et al. Evaluation of Tubulointerstitial Lesions'Severity in Patients with Glomerulonephritides: An NMR-Based Metabonomic Study[J]. Proteome Res, 2007, 6(9):3760-3770.
[23] Holmes E, Connor SC, Nicholls AW, et al. The identification of novel biomark2ers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine[J]. Chemometri Intell Lab Sys, 1999, 44: 245-255.
[24] Mäkinen V P, Soininen P, Forsblom C, et al. Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum[J]. MAGMA, 2006, 19(6):281-296.
[25] Yang J, Xu GW, Hong Q, et al. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles[J]. Chromatogr B Analyt Technol Biomed Life Sci, 2004, 813(1-2): 53-58.
[26] Yuan K, Kong H, Guan Y, et al. A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile[J]. Chromatogr B Analyt Technol Biomed Life Sci, 2007, 850(1-2):236-240.
[27] Xu GW, Liebich H. Normal and modified nucleosides in urine as potential tumor markers determined by MEKC and HPLC[J]. Am Clin Lab, 2001 ;20:22-32.
[28] Yang J, Xu GW, Kong HW, et al. Artificial neural network classification based on high-performance liquid chromatography of urinary and serum nucleosides for the clinical diagnosis of cancer[J]. J Chro-matogr B, 2002, 780(1):27-33.
[29] Zheng YF, Xu GW, Liu DY, et al. Study of urinary nucleosides as biological marker in cancer patients analyzed by micellar electrokinetic capillary chromatography[J]. Electrophoresis, 2002, 23(24):4104-4109.
[30] Hewer R, Vorster J, Steffens F E, et al. Applying biofluid1H NMR-based metabonomic techniques to distinguish between HIV-1 positive AIDS patients on antiretroviral treatment and HIV-1 negative individuals[J]. Pharm Biomed Anal, 2006, 41(4):1442-1446.